Health Canada Approves New Indication for Zytiga for Treatment of Hormone-Sensitive Prostate Cancer

Health Canada Approves New Indication for Zytiga for Treatment of Hormone-Sensitive Prostate Cancer
Health Canada recently approved Zytiga (abiraterone acetate) in combination with prednisone and androgen deprivation therapy (ADT) for the treatment of patients with newly diagnosed, high-risk metastatic hormone-sensitive prostate cancer (mHSPC) who may have previously received up to three months of ADT. Janssen Pharmaceutical Companies of Johnson & Johnson announced the Canadian approval just one week

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Ben Adams says:

    I remember reading this therapy is linked to dementia so I would be scared to try with this one; I always try to go for natural remedies so I dont have to worry about the side effects, I dont have prostate cancer but I had few symptoms and I didnt pay attention to them until it got serious and tried different prostate supplements until I had to see a urologist, He prescribed me alpharise for my prostate, its 100% natural and after 5 months taking it I am happy with the results and I have not had any side effect.

Leave a Comment

Your email address will not be published. Required fields are marked *